Our study provides rationale to further investigate the involvement of fatty acid metabolism signaling pathway in NSCLC development as well as FABP3 and FABP4 as potential prognostic markers and therapeutic targets in NSCLC. The gene discussed is FABP3; the disease is non-small cell lung carcinoma.